Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWong, Anselm-
dc.contributor.authorLandersdorfer, Cornelia-
dc.contributor.authorGraudins, Andis-
dc.identifier.citationEuropean Journal of Clinical Pharmacology 2017; 73(9): 1103-1110en_US
dc.description.abstractPURPOSE: Paracetamol overdose is common and is treated with acetylcysteine to prevent the development of hepatotoxicity. N-acetyl-p-benzoquinone imine (NAPQI) is the toxic metabolite of paracetamol overdose. We aimed to assess the expected acetylcysteine concentration time profiles following delivery of modified acetylcysteine regimens proposed for those at high and low risk of hepatotoxicity. In addition, we will determine acetylcysteine concentrations post-cessation of abbreviated infusions. METHOD: We performed pharmacokinetic simulations using Berkeley Madonna (version comparing the time course of acetylcysteine concentration during and after the cessation of an abbreviated 12-h regimen (250 mg/kg) using a two-bag infusion and compared this to the standard 21-h three-bag (300 mg/kg) regimen. We also simulated extended duration acetylcysteine regimens and other increased dosing strategies that have been recommended in specific paracetamol poisoning scenarios. RESULTS: A more sustained serum concentration is achieved when the acetylcysteine loading dose is delivered over 4 h using the two-bag compared to the 1-h loading dose of the three-bag regimen. When administering an abbreviated 12-h acetylcysteine regimen, circulating acetylcysteine is detectable for 8 h after cessation of the infusion. This may provide a continued hepatoprotective effect if NAPQI is still being generated after the infusion is ceased. CONCLUSION: This pharmacokinetic simulation study is an important step in determining plasma acetylcysteine concentrations that are likely to be achieved using various modified treatment regimens. Importantly, for patients at low risk of liver injury after acute overdose, acetylcysteine is likely to be detectable many hours post-cessation of a 12-h regimen. This should provide a safety factor against development of hepatotoxicity for any ongoing paracetamol metabolism after cessation of the acetylcysteine infusion.en_US
dc.titlePharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoningen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean Journal of Clinical Pharmacologyen_US
dc.identifier.affiliationSchool of Clinical Sciences, Department of Medicine, Monash University, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationVictorian Poisons Information Centre and Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationCentre for Medicine and Safety Use, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationMonash Emergency Research Collaborative, Monash Health, Clayton, Victoria, Australiaen_US
dc.type.austinJournal Articleen_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristype Poisons Information Centre- Poisons Information Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.